(VIANEWS) – The NASDAQ ended the session with Arcturus Therapeutics rising 13.41% to $29.18 on Wednesday, after five sequential sessions in a row of losses. NASDAQ fell 1.17% to $13,722.02, following the last session’s downward trend on what was an all-around negative trend exchanging session today.
Arcturus Therapeutics’s last close was $25.73, 31.84% under its 52-week high of $37.75.
About Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Arcturus Therapeutics has a trailing twelve months EPS of $4.25.
PE Ratio
Arcturus Therapeutics has a trailing twelve months price to earnings ratio of 6.87. Meaning, the purchaser of the share is investing $6.87 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 43.3%.
More news about Arcturus Therapeutics (ARCT).
